Key opinion leaders review clinical cases in systemic mastocytosis, focusing on therapeutic options and diagnostic criteria.
EP. 1: Systemic Mastocytosis: Epidemiology and Diagnostic Criteria
Experts in the field of mast cell disorders discuss the epidemiology and diagnostic criteria of systemic mastocytosis.
EP. 2: Considerations in Mast Cell Disorders
The panel of experts highlights the importance of assessing symptomology and clinical characteristics in mast cell disorders.
EP. 3: Considerations in SM: Hereditary Alpha Tryptasemia
Prithviraj Bose, MD, and Patricia Lugar, MD, MS, discuss the considerations and testing options for hereditary alpha tryptasemia in patients with systemic mastocytosis.
EP. 4: Case 1: 75-Year-Old Man With SM
Dan DeAngelo, MD, PhD, presents the case of a 75-year-old man with systemic mastocytosis and reviews WHO diagnostic criteria.
EP. 5: Case 1: Treatment and Management Considerations
The panel of experts in SM discuss the diagnosis and management of a 75-year-old man with systemic mastocytosis.
EP. 6: Case 1: Treatment Algorithm and Supportive Care Recommendations
Patricia Lugar, MD, MS, shares treatment algorithm and supportive care recommendations for a 75-year-old man with systemic mastocytosis.
EP. 7: Case 2: 46-year-old Woman With SM
Dan DeAngelo, MD, PhD, presents the case of a 46-year-old woman with systemic mastocytosis and associated gastrointestinal symptoms.
EP. 8: Case 2: Treatment and Management Considerations for SM
The panel of experts in SM discuss the diagnosis and management of a 46-year-old woman with systemic mastocytosis.
EP. 9: Case 2: SM Treatment Algorithm and Supportive Care Recommendations
Patricia Lugar, MD, MS, shares an allergist’s perspective regarding treatment algorithms and supportive care recommendations for patients with systemic mastocytosis.
EP. 10: PATHFINDER Trial Efficacy Data
Dan DeAngelo, MD, PhD, reviews key efficacy data from the phase II PATHFINDER study.
EP. 11: Avapritinib: Approval and Clinical Practice Implications
A panel of experts share their reactions to the approval of avapritinib and discuss the clinical implications.
EP. 12: Case 3: Indolent Systemic Mastocytosis
Dan DeAngelo, MD, PhD, presents the case of a patient with indolent systemic mastocytosis and urticaria pigmentosa.
EP. 13: Case 4: A 68-Year-Old Female With Mast Cell Leukemia
Sa Wang, MD, presents the case of a 68-year-old female with mast cell leukemia.
EP. 14: Case 4: Treatment and Management Considerations in MCL
The panel of experts in SM discuss the diagnosis and treatment of a 68-year-old female with mast cell leukemia.
EP. 15: Advanced Systemic Mastocytosis: Expert Insight into Epidemiology, Diagnosis, and Treatment
Learn more about the epidemiology, diagnosis, and treatment of advanced systemic mastocytosis in this summary from an expert multidisciplinary case-based discussion.
EP. 16: Case 5: A 24-Year-Old Female With Well-Differentiated SM
Sa Wang, MD, presents the case of a 24-year-old female with well-differentiated systemic mastocytosis.
EP. 17: Well-Differentiated Systemic Mastocytosis vs Chronic Mast Cell Leukemia
The panel of experts discuss the clinical differences between well-differentiated systemic mastocytosis and chronic mast cell leukemia.
EP. 18: Case 6: 47-Year-Old Male With Leukocytosis, Anemia, and Splenomegaly
Sa Wang, MD, presents the case of a 47-year-old male with leukocytosis, anemia, and splenomegaly.
EP. 19: Chronic Myelomonocytic Cell Leukemia: Clinical Considerations
The panel of experts discuss the diagnosis and assessment of chronic myelomonocytic cell leukemia.
EP. 20: Unmet Needs in SM Treatment
The panel of experts in SM highlight the unmet needs in the clinical care of systemic mastocytosis.
IDE397 Shows Early Antitumor Activity, Safety in MTAP-Deletion Urothelial Cancer and NSCLC
RVU120 Shows Early Promise in R/R Metastatic or Advanced Solid Tumors
The WEE1 Inhibitor APR-1051 Shows Early Safety and Tolerability in Advanced, Mutated Solid Tumors
TYRA-300 Is Safe, Generates Preliminary Antitumor Activity in FGFR3+ Metastatic Urothelial Cancer